Drug Trial Radar · NCT00986037
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma
Last checked: Nov 19, 2026Latest source record: Nov 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Planned (sponsor's estimate)
Start
Oct 2009
Primary completion
Jul 2010
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.
Conditions
- Asthma
Interventions
ABT-308Drug
Single IV doses
ABT-308Drug
Multiple SC doses x 3
PlaceboDrug
Single IV dose
PlaceboDrug
Multiple SC doses x 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments.Time frame: 12 weeks after last dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.